The ASCENT DR-TB project, funded by Unitaid and led by the KNCV Tuberculosis Foundation, aims to improve access to shorter, safer and more effective treatment regimens for drug-resistant TB (DR-TB) and comprehensive, person-centered packages of quality care.

Treatment Action Group (TAG) leads the community and civil society engagement (CCSE) component of the ASCENT DR-TB Project. At the heart of the CCSE program is a catalytic small grants program in which selected partners received modest funding to undertake advocacy and community work in support of person-centered DR-TB treatment with BPaL/M and other WHO-recommended regimens.

Through this program, TAG awarded catalytic small grants to nine organizations in seven countries to facilitate treatment literacy, community-led demand creation, and policy advocacy activities to increase access to BPaL/M and other WHO-recommended treatment regimens for DR-TB and patient-centered care and support. Here we feature the work and achievements of community and civil society organizations funded under ASCENT DR-TB CCSE program.